I-WISh: IS AN EXPERT PHYSICIAN, PATIENT ADVOCACY DESIGNED AND ENDORSED, CROSS-SECTIONAL SURVEY THAT SOUGHT TO PROVIDE INSIGHTS ON THE BURDEN OF ITP AND ITS IMPACT ON PATIENT QoL USING A GLOBAL PATIENT AND PHYSICIAN SAMPLING FRAME1
Objective
The aim of I-WISh is to investigate differences between patients’ and physicians’ perceptions of symptom burden, treatment goals and disease management.1
Number of respondents and method
- 1507 patients and 472 physicians completed the survey from the 13 countries1
- Patient numbers per country: Canada (n=61), China (n=286), Colombia (n=51), Egypt (n=0), France (n=87), Germany (n=82), India (n=65), Italy (n=74), Japan (n=56), Spain (n=48), Turkey (n=60), UK (n=120) and US (n=501)2
- Patients completed a 30-minute online survey providing information on their demographic background, their experience of being diagnosed, current health state, symptoms experienced, the impact on QoL, as recorded by the ITP Life Quality Index (ILQI), and the emotional burden of the condition2
Patients
- Mean (SD) patient age at survey completion was 47.1 (SD: 16.17) years1,2
- Patients were recruited via patient association group (PAG) or treating physician2
- Patients had been diagnosed with ITP for an average of 9.0 (SD, 10.78) years2
- 64% of patients described their current health state as ≥5 using a 7-point Likert scale (7 is excellent health), whilst 32% described their health state as low (1–4 score, where 1 is very poor health)2
Abbreviations: ILQI, ITP Life Quality Index; ITP, immune thrombocytopenia; I-WISh, ITP World Impact Survey; PAG, patient association group; QoL, quality of life; SD, standard deviation.
References:
- Kruse A, et al. Presented at EHA 24th Annual Congress, Amsterdam, Netherlands, June 13–16, 2019. PF711.
- Data on file. I-WISh global study (REVDOF001).
HCP19-C002i(1) June 2020.